Incyte to establish European headquarters in Geneva

Wednesday, July 15, 2020 @ 12:00 am

New facility to serve as European base for Incyte’s drug development operations, and provides efficient access to key clinical trial experts and institutions.

Incyte Corporation (Nasdaq:INCY) announced that it will establish the new headquarters of Incyte Europe S.a.r.l (“Incyte Europe”) in Geneva, Switzerland. Incyte intends to use Incyte Europe as the base from which it will conduct its European clinical development operations, and expects to occupy the 9,000 sq. ft. facility by mid-2015.

“The establishment of Incyte Europe in Geneva is a natural step in our company’s evolution,” said Hervé Hoppenot, President and CEO of Incyte Corporation. “Incyte has a broad and growing pipeline of proprietary, wholly-owned products, and we expect that this new facility in the center of Europe will enable us to create the infrastructure needed to support our global drug development programs, and to bring additional, potentially life-changing medicines to patients with cancer.”

“Geneva is especially pleased to welcome a biotechnology leader such as Incyte to our city,” said, Mr. Pierre Maudet, Minister of the Department of Security and Economy for the Republic and Canton of Geneva. “We are confident that Incyte will benefit from the international talent pool in Geneva and the surrounding region, and that the company’s presence will further enhance Geneva’s standing as an important hub in the biotechnology industry.”

You may also be interested in

Swiss Biotech Report 2024 shows sector performing well in 2023 by continuing to embrace international alliances

Record revenues of CHF 7.3 billion (USD 8.1 billion) – Capital investments increase by more than 50% to CHF 2 billion – CHF 1.4 billion by public companies, CHF 0.6 billion by private companies – Significant licensing and M&A activity in 2023 – VectivBio, T3, Vertex, Santhera – R&D investments of publicly traded biotech companies have decreased in line with global markets, wherea
April 23, 2024

AC Immune and Takeda sign agreement for an Alzheimer immunotherapy

Takeda to receive exclusive option to license global rights to ACI-24.060, a potential first-in-class active immunotherapy designed to delay or slow Alzheimer’s disease progression AC Immune to receive upfront payment of $100 million upon closing and be eligible for an option exercise fee and additional potential milestones of up to approximately $2.1 billion AC Immune to host conference call an
May 13, 2024

Memo Therapeutics increases series C financing to CHF 45 million

Additional CHF 20 million raised from new investors Ysios Capital and Kurma Partners as well as from existing investors Proceeds will be used to expand Phase II of best-in-class anti-BK Virus antibody to become the largest study ever conducted for BK virus infection in kidney transplantation in kidney transplantation
May 7, 2024

Mabylon: Candidate nomination of an anti-allergen multispecific antibody for peanut allergy

In collaboration with Pfizer Ignite, Mabylon nominates its anti-allergen multispecific antibody product that is undergoing Investigative New Drug (IND)-enabling studies and subsequent clinical development for the treatment of peanut allergy.
May 10, 2024

Solvias builds biologics and cell & gene therapy testing center in the US

Global provider continues to expand analytical service capabilities for life science companies developing advanced treatments for cancer and rare diseases
May 6, 2024

BioVersys: More collaboration with GSK and series C round of CHF 12.3 million

Strategic collaboration with GSK expanded to accelerate clinical development of alpibectir for the treatment of tuberculosis GSK to participate in Series C Extension with equity investment Series C financing round extended overall by CHF 12.3 million to CHF 44.9 million
May 7, 2024